2. Vías de señalización
  3. Immunology/Inflammation
  4. Interleukin Related
  5. Interleukin Related Isoform
  6. Interleukin Related Antagonist

Interleukin Related Antagonist

Interleukin Related Antagonists (18):

Cat. No. Nombre del producto Efecto Pureza
  • HY-P990023
    Bempikibart
    		Antagonist 98.00%
    Bempikibart (ADX-914) is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and thymic stromal lymphopoietin (TSLP). Bempikibart can be used for the study of atopic dermatitis and alopecia areata.
  • HY-P99256
    Tildrakizumab
    		Antagonist 99.46%
    Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis.
  • HY-P9927A
    Secukinumab (Anti-Human IL-17A)
    		Antagonist 98.31%
    Secukinumab (Anti-Human IL-17A) is a fully human anti-interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis.
  • HY-P99645
    Goflikicept
    		Antagonist 98.32%
    Goflikicept (RPH 104) is a fusion protein that selectively binds and inactivates both circulating IL-1β and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI).
  • HY-172660
    36R-D481
    		Antagonist
    36R-D481 is a competitive and orthosteric antagonist of IL-36R, effectively inhibiting IL-36 signaling. 36R-D481 can inhibit IL-36α and IL-36γ but not IL-36β induced IL-8 release.
  • HY-169859
    EP4 receptor antagonist 7
    		Antagonist 99.9%
    EP4 receptor antagonist 7 (Compound 14) is an antagonist of the prostaglandin E2 (PGE2) receptor subtype EP4 with an IC50 value of 1.1 nM. EP4 receptor antagonist 7 inhibits PGE2-induced β-arrestin recruitment in HEK293 cells with an IC50 value of 0.9 nM. EP4 receptor antagonist 7 decreases PGE2-induced expression of mRNA encoding IL-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1), in RAW 264.7 macrophages. EP4 receptor antagonist 7 combined with an anti-PD-1 antibody inhibits tumor growth and increases infiltration of CD8+ T cells into tumors in a CT26 murine colon cancer model.
  • HY-P992033
    Anti-Mouse IL-4Rα Antibody (REGN1103)
    		Antagonist
    Anti-Mouse IL-4Rα Antibody (REGN1103) is a mouse homologous antibody targeting IL-4Rα, as well as an inhibitor of IL-4 signaling. Anti-Mouse IL-4Rα Antibody (REGN1103) can be used in studies related to alveolar rhabdomyosarcoma.
  • HY-148693
    OSM-SMI-8
    		Antagonist
    OSM-SMI-8 (NSC642624) is a potent OSM (oncostatin M) antagonist. OSM-SMI-8 has the potential for the research of cancer.
  • HY-P11623
    4L2-P13D
    		Antagonist
    4L2-P13D is an IL-11 antagonist with an IC50 of 2.8 μM. 4L2-P13D has a KD of 11 nM for hIL-11. 4L2-P13D exhibits antifibrotic and renoprotective activities. 4L2-P13D can be used in the research of renal fibrosis.
  • HY-148693A
    (E/Z)-OSM-SMI-8
    		Antagonist
    (E/Z)-OSM-SMI-8 is the racemate of OSM-SMI-8 (HY-148693). OSM-SMI-8 is the antagonist for OSM (oncostatin M), that exhibits the potential in anti-cancer research.
  • HY-18263
    Elubrixin hydrochloride
    		Antagonist
    Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin hydrochloride inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin hydrochloride has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
  • HY-P992032
    TPP-9476
    		Antagonist
    TPP-9476 (BAY-943 antibody) is an anti-human IL3RA (CD123) monoclonal antibody with human IL3RA Kd of 11 nM and cynomolgus monkey IL3RA Kd of 16 nM. TPP-9476 binds specifically to human and cynomolgus monkey IL3RA, undergoes target-dependent internalization into lysosomes of IL3RA-positive cells.TPP-9476 exerts antiproliferative effects in IL3RA-expressing acute myeloid leukemia and classical Hodgkin lymphoma cells, reduces tumor burden, improves survival, and induces complete tumor remission in relevant xenograft mouse models.
  • HY-103390
    Ro26-4550 TFA
    		Antagonist
    Ro26-4550 TFA is a low micromolar antagonist of IL-2/IL-2Rα binding with an IC50 value of 3 μM.
  • HY-P992035
    AMY109
    		Antagonist
    AMY109 is an anti-human interleukin-8 (IL-8) monoclonal antibody, with a Ka of 36.8 pM for human IL-8, and a Ka of 380 pM for cynomolgus monkey IL-8. AMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of CXCR1 and CXCR2, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein-1 production by neutrophils. AMY109 is applicable to research related to endometriosis.
  • HY-121743
    Ro26-4550
    		Antagonist
    Ro26-4550 is a low micromolar antagonist of IL-2/IL-2Rα binding with an IC50 value of 3 μM.
  • HY-101915R
    IL-17A antagonist 3 (Standard)
    		Antagonist
    IL-17A antagonist 3 (Standard) is the analytical standard of IL-17A antagonist 3 (HY-101915). This product is intended for research and analytical applications. IL-17A antagonist 3 is an IL-17A antagonist, compound 3.
  • HY-18263CR
    Elubrixin tosylate (Standard)
    		Antagonist
    Elubrixin (tosylate) (Standard) is the analytical standard of Elubrixin (tosylate). This product is intended for research and analytical applications. Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation.
  • HY-101913R
    IL-17A antagonist 1 (Standard)
    		Antagonist
    IL-17A antagonist 1 (Standard) is the analytical standard of IL-17A antagonist 1 (HY-101913). This product is intended for research and analytical applications. IL-17A antagonist 1 (compound 1) is an IL-17A antagonist, with a Kd of 0.66 μM and an IC50 of 1.14 μM.